menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Keys to the Latest NLA Recommendations for Dyslipidemia Treatments

Keys to the Latest NLA Recommendations for Dyslipidemia Treatments
RestartResume
What's the evidence for LDL and other non-HDL targets for primary and secondary prevention of heart disease? What are the comparative benefits vers...
  • Overview

    What's the evidence for LDL and other non-HDL targets for primary and secondary prevention of heart disease? What are the comparative benefits versus toxicities of all lipid-lowering medications in clinical use? Addressing these and other questions from the standpoing of recent NLA recommendations is Kevin Maki, PhD, FNLA, CLS, Chief Science Officer for Midwest Center for Metabolic and Cardiovascular Research and Adjunct Faculty in Biostatistics and Applied Epidemiology at DePaul University, Chicago, IL. 

    Produced in partnership with

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/12/19